Clinical trial · Observational
Pneumococcal Vaccination in Patients With Chronic Lymphocytic Leukaemia
Immunogenicity of the Currently Recommended Pneumococcal Vaccination Schedule in Patients With Chronic Lymphocytic Leukaemia.
NCT05145101CI-TRIAL-00055590Pneumo-CLLunknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
In this study the antibody response after vaccination with the 13-valent pneumococcal conjugated vaccine (PCV13) followed 2 months later by the 23-valent polysaccharide vaccine (PPSV23) in adults with chronic lymphocytic leukemia will be investigated.
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Chronic Lymphocytic Leukemia | Chronic Lymphocytic Leukemia | ONTOLOGY_EXACT | 0.98 |
| Invasive Pneumococcal Disease, Recurrent Isolated | — | UNRESOLVED | — |
| Pneumococcal Infections | — | UNRESOLVED | — |
| Vaccine-Preventable Diseases | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Prevnar13 | Biological | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- serologic response rate
- timeFrame
- 1-2 months after vaccination schedule
- description
- Proportion of participants with a ≥4-fold increase in serotype specific anti-pneumococcal IgG for ≥6/9 serotypes
Secondary outcomes (2)
- measure
- Serologic protection rate
- timeFrame
- 1-2 months after vaccination
- description
- Antibody concentration ≥1.3 mcg/ml for ≥6/9 serotypes
- measure
- Geometric mean concentrations of serotype specific anti-pneumococcal IgG for 9 pneumococcal serotypes
- timeFrame
- Month 0, month 4
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * CLL * Age \>17 * Naive to pneumococcal vaccination Exclusion Criteria: * Not able/willing to participate
References
Publications (0)
Data not yet available
No reference posted for this study.